Short Report Sparks Debate: Recent posts on X have been buzzing with discussion about Praxis Precision Medicines (PRAX) following a critical short report from a research firm. The report alleges questionable data practices in the company’s Phase 3 trial for ulixacaltamide, a drug for essential tremor, causing a sharp drop in stock price. Many users on the platform are expressing concern over the credibility of the trial results.
Upcoming Data Call: Adding to the conversation, Praxis announced a fireside chat on November 24, 2025, to discuss the ulixacaltamide clinical data, which some on X see as a chance for the company to address criticisms. A few users noted a slight price recovery after the announcement, hinting at cautious optimism. The event is drawing significant attention as investors await clarity.
Insider Sales Raise Eyebrows: Further fueling discussion, recent insider sales by company executives have been highlighted on X, with some users questioning the timing amidst the ongoing controversy. While not necessarily indicative of internal issues, these moves are stoking speculation and adding to the uncertainty surrounding PRAX.
Note: This discussion summary was generated from an AI condensation of post data.
Praxis Precision Medicines Insider Trading Activity
Praxis Precision Medicines insiders have traded $PRAX stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. ADAGE has made 0 purchases and 10 sales selling 313,910 shares for an estimated $33,198,123.
- ALEX NEMIROFF (General Counsel and Secretary) has made 0 purchases and 4 sales selling 25,130 shares for an estimated $4,852,255.
- LAUREN MASTROCOLA (Principal Accounting Officer) has made 0 purchases and 2 sales selling 13,600 shares for an estimated $2,612,243.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Praxis Precision Medicines Hedge Fund Activity
We have seen 86 institutional investors add shares of Praxis Precision Medicines stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC removed 989,985 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,628,869
- CAPITAL RESEARCH GLOBAL INVESTORS removed 853,746 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,900,019
- PERCEPTIVE ADVISORS LLC added 811,633 shares (+107.8%) to their portfolio in Q3 2025, for an estimated $43,016,549
- CORMORANT ASSET MANAGEMENT, LP removed 625,000 shares (-38.5%) from their portfolio in Q3 2025, for an estimated $33,125,000
- MORGAN STANLEY removed 582,844 shares (-47.5%) from their portfolio in Q3 2025, for an estimated $30,890,732
- POINT72 ASSET MANAGEMENT, L.P. added 541,911 shares (+56.8%) to their portfolio in Q3 2025, for an estimated $28,721,283
- PRICE T ROWE ASSOCIATES INC /MD/ removed 469,585 shares (-31.9%) from their portfolio in Q3 2025, for an estimated $24,888,005
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Praxis Precision Medicines Analyst Ratings
Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 10 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Wedbush issued a "Underperform" rating on 11/06/2025
- Chardan Capital issued a "Buy" rating on 10/17/2025
- Deutsche Bank issued a "Buy" rating on 10/17/2025
- Truist Securities issued a "Buy" rating on 10/17/2025
- Guggenheim issued a "Buy" rating on 10/17/2025
To track analyst ratings and price targets for Praxis Precision Medicines, check out Quiver Quantitative's $PRAX forecast page.
Praxis Precision Medicines Price Targets
Multiple analysts have issued price targets for $PRAX recently. We have seen 12 analysts offer price targets for $PRAX in the last 6 months, with a median target of $269.0.
Here are some recent targets:
- Kambiz Yazdi from BTIG set a target price of $424.0 on 11/19/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $258.0 on 11/13/2025
- Laura Chico from Wedbush set a target price of $77.0 on 11/06/2025
- David Hoang from Deutsche Bank set a target price of $280.0 on 10/17/2025
- Joon Lee from Truist Securities set a target price of $360.0 on 10/17/2025
- Yatin Suneja from Guggenheim set a target price of $350.0 on 10/17/2025
- Rudy Li from Chardan Capital set a target price of $330.0 on 10/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
